AstraZeneca's CALQUENCE combined with chemoimmunotherapy reduced disease progression or death risk by 27% in untreated mantle cell lymphoma patients in the ECHO trial.

AstraZeneca's CALQUENCE (acalabrutinib) combined with chemoimmunotherapy reduced disease progression or death risk by 27% compared to standard care in previously untreated mantle cell lymphoma patients in the ECHO Phase III trial. This combination showed a statistically significant and clinically meaningful improvement in progression-free survival, with a favorable trend in overall survival.